loading...| Preferred Name |
Ziv-Aflibercept |
|
| Synonyms |
VEGF Trap R1R2 Vascular Endothelial Growth Factor Trap Ziv-aflibercept aflibercept Aflibercept vascular endothelial growth factor trap AFLIBERCEPT Ziv-Aflibercept AVE0005 Eylea VEGF Trap VEGF-Trap Zaltrap |
|
| Definitions |
A recombinant protein comprised of epitopes of the extracellular domains of human vascular endothelial growth factor receptors (VEGFR) fused to the constant region (Fc) of human IgG1 with potential antiangiogenic activity. Afilbercept, functioning as a soluble decoy receptor, binds to pro-angiogenic vascular endothelial growth factors (VEGFs), thereby preventing VEGFs from binding to their endogenous receptors. Disruption of the binding of VEGFs to their cellular receptors may result in the inhibition of tumor angiogenesis, metastasis, and ultimately tumor regression. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C2682 |
|
| ALT_DEFINITION |
A substance being studied in the treatment of several types of cancer. Vascular endothelial growth factor trap blocks the action of vascular endothelial growth factor (VEGF) and may prevent the growth of new blood vessels that tumors need to grow. It is a type of antiangiogenesis agent. |
|
| CAS_Registry |
862111-32-8 |
|
| code |
C2682 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc |
|
| DEFINITION |
A recombinant protein comprised of epitopes of the extracellular domains of human vascular endothelial growth factor receptors (VEGFR) fused to the constant region (Fc) of human IgG1 with potential antiangiogenic activity. Afilbercept, functioning as a soluble decoy receptor, binds to pro-angiogenic vascular endothelial growth factors (VEGFs), thereby preventing VEGFs from binding to their endogenous receptors. Disruption of the binding of VEGFs to their cellular receptors may result in the inhibition of tumor angiogenesis, metastasis, and ultimately tumor regression. |
|
| Display_Name |
Ziv-Aflibercept |
|
| FDA_UNII_Code |
15C2VL427D |
|
| FULL_SYN |
VEGF Trap R1R2 Vascular Endothelial Growth Factor Trap Ziv-aflibercept aflibercept Aflibercept vascular endothelial growth factor trap AFLIBERCEPT Ziv-Aflibercept AVE0005 Eylea VEGF Trap VEGF-Trap Zaltrap |
|
| Has_Target | ||
| Is_Value_For_GDC_Property | ||
| label |
Ziv-Aflibercept |
|
| Legacy Concept Name |
VEGF_Trap |
|
| Maps_To |
Ziv-Aflibercept |
|
| NCI_Drug_Dictionary_ID |
38652 |
|
| NSC Number |
724770 |
|
| PDQ_Closed_Trial_Search_ID |
38652 |
|
| PDQ_Open_Trial_Search_ID |
38652 |
|
| Preferred_Name |
Ziv-Aflibercept |
|
| prefixIRI |
Thesaurus:C2682 |
|
| Semantic_Type |
Pharmacologic Substance Immunologic Factor |
|
| UMLS_CUI |
C1134659 |
|
| subClassOf |